InMed Pharmaceuticals

InMed Pharmaceuticals

Yahoo Finance • 13 days ago

Pre-Market Movers: TNGX, WOK, GOCO Set The Path

(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, hinting at possible breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. Price swings ahead of t... Full story

Yahoo Finance • 25 days ago

Halper Sadeh LLC is Investigating Whether D, AVB, INM, EQR are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • 25 days ago

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—D, INM, ESQ, and GDOT

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the... Full story

Yahoo Finance • last month

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of InMed Pharmaceuticals, Inc. (NASDAQ: INM) 

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the... Full story

Yahoo Finance • last month

InMed and Mentari announce all-stock merger deal

[M&A Mergers And Acquisitions] narvo vexar Canadian pharmaceutical company InMed Pharmaceuticals (INM [https://seekingalpha.com/symbol/INM]) added ~170% in the premarket on Tuesday after announcing an all-stock merger agreement with migra... Full story

Yahoo Finance • 3 months ago

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates target... Full story

Yahoo Finance • 6 months ago

Life Sciences Virtual Investor Forum Agenda Announced for December 11th

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Life Sciences Virtual Investor Forum to be held December 11th. Individual investo... Full story

Yahoo Finance • 7 months ago

InMed Pharmaceuticals GAAP EPS of -$0.44

* InMed Pharmaceuticals press release [https://seekingalpha.com/pr/20298167-inmed-reports-first-quarter-fiscal-2026-financial-results-and-provides-business-update] (INM [https://seekingalpha.com/symbol/INM]): Q1 GAAP EPS of -$0.44. * A... Full story

Yahoo Finance • 9 months ago

InMed Pharmaceuticals GAAP EPS of -$8.36, revenue of $4.94M

* InMed Pharmaceuticals press release [https://seekingalpha.com/pr/20241081-inmed-pharmaceuticals-reports-full-year-fiscal-2025-financial-results-and-provides-business] (NASDAQ:INM [https://seekingalpha.com/symbol/INM]): FY GAAP EPS of -... Full story

Yahoo Finance • 9 months ago

Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18th are now a... Full story

Yahoo Finance • 12 months ago

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates fo... Full story

Yahoo Finance • 12 months ago

InMed Pharmaceuticals announces $5M private placement

* InMed Pharmaceuticals (NASDAQ:INM [https://seekingalpha.com/symbol/INM]) has entered into definitive agreements for the issuance and sale of 1.95M of its common shares and short-term preferred investment options to purchase up to an ag... Full story

Yahoo Finance • 12 months ago

InMed's Alzheimer's drug candidate shows reduced inflammation in lab tests

VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ:INM), a micro-cap pharmaceutical company with a market capitalization of approximately $3 million, announced Tuesday that its drug candidate INM-901 significantly reduced inflammation markers... Full story

Yahoo Finance • last year

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates fo... Full story

Yahoo Finance • 3 years ago

Presenting on the Emerging Growth Conference on March 8 Register Now

MIAMI, March 07, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 51st Emerging Growth Conference on March 8, 2023. The Emerging Growth Conference identifies companie... Full story

Yahoo Finance • 3 years ago

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

Closed calendar year 2022 with strong cash position of $11.5 millionApproaches completion of enrollment for Ph 2 clinical trial in EBAdvances research using rare cannabinoids in treating glaucoma and neurodegenerative diseases such as Alzh... Full story

Yahoo Finance • 3 years ago

InMed Provides Business Update and Milestones for 2023

Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023Progress preclinical research in glaucoma in preparation for human trialsAdvance research using rare cannabinoids in treating neurodegenerative diseases such as... Full story

Yahoo Finance • 4 years ago

InMed Announces Results of 2022 Annual General Meeting

VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story

Yahoo Finance • 4 years ago

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

VANCOUVER, British Columbia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story

Yahoo Finance • 4 years ago

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

VANCOUVER, British Columbia, Nov. 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story